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ABSTRAK 
Latar belakang: Computed tomografi (CT) mungkin menunjukkan ciri-ciri tertentu 
Invasif Pulmonari Aspergillosis (IPA). Ciri-ciri ini  termasuk Airway invasif dan Angio 
Invasif. Walau bagaimanapun kedua-dua jenis penemuan CT ini tidak khusus untuk IPA 
dan diagnosis mesti berdasarkan EORTC-MSG. Tujuan kajian  ini adalah mencari 
perkaitan di antara ciri CT dada dengan Galactomannan(GM) dan  Aspergillus-spesifik 
polymerase chain reaction(PCR)  bagi pesakit yang mengalami  febrile neutropenia. 
 
Kaedah: Kesemua pesakit kanser darah yang mengalami febrile neutropenia  3 hari atau 
lebih walaupun telah dirawat dengan antibiotik akan menjalani ujian CT dada dalam  
masa 2 minggu. Penemuan CT dada akan direkod dan perkaitan  antara jenis penemuan 
CT dan GM serta PCR dikaji  menggunakan ‘Fisher  exact  test’. (Nilai p signifikan 
<0.05). 
 
Keputusan: Seramai  26 pesakit  telah dimasukkan dalam kajian ; 17 (65.4%) CT dada 
adalah positif , di mana 8 (30.8%) positif untuk Galactomannan dan 9 (34.6%) untuk 
PCR. Terdapat hubungan yang ketara antara penemuan PCR  dan  CT dada (p value 
0.009, 95% CI) tetapi tidak antara Galactomannan dan CT dada (nilai p 0.667, 95% CI). 
 
Kesimpulan: Kombinasi di antara PCR dan CT dada boleh digunakan sebagai salah satu 
cara noninvasive untuk mengesan pesakit  IPA dengan  seawal mungkin.  Aspergillus -
spesifik PCR mungkin boleh dimasukkan sebagai salah  satu kriteria mycology dalam  
EORTC-MSG  untuk  mengesan   IPA  pada  masa  akan datang. 
 
Kata Kunci: Invasive Pulmonary Aspergillosis, galactomannan, Polymerase chain 
xi  
reaction,Radiography thoracic, febrile neutropenia 
xii  
ABSTRACT 
Background: The Computed Tomography (CT) features of Invasive Pulmonary 
Aspergillosis (IPA) include Airway and Angio Invasive type. However those features are 
nonspecific and diagnosis should be made in conjunction with EORTC-MSG criteria. In 
this study, we evaluated the association between the CT findings and Galactomannan and 
Aspergillus specific PCR in patient with febrile neutropenia. 
 
Methods: Patients with hematological malignancy who had persistent febrile 
neutropenia of 3 days or more despite of antibiotic underwent CT thorax within 2 weeks 
of clinical diagnosis of IPA. Blood serum for Galactomannan assay and Aspergillus 
specific PCR were performed. Changes of CT thorax were documented and association 
between mycological findings were analyzed using Fisher exact test. Significant 
association taken at p value of < 0.05.  
 
Results: A total of 26 patients were enrolled in our study. CT findings were positive in 
17(65.4%), 8(30.8%) was positive for Galactomannan and 9(34.6%) for PCR. There was 
significant association between PCR and CT thorax finding (p value 0.009, 95% CI) but 
not between Galactomannan and CT Thorax (p value 0.667, 95% CI). 
 
Conclusion: Combination of PCR and CT thorax can be used as a non-invasive tools for 
early diagnosis of IPA. The Aspergillus specific PCR might to be consider as one of the 
mycological criteria in EORTC-MSG for diagnosis of IPA in the future. 
 
Keywords: Invasive Pulmonary Aspergillosis, galactomannan, Polymerase chain 
reaction, Radiography thoracic, febrile neutropenia 
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CHAPTER 1   : INTRODUCTION & LITERATURE 
REVIEW 
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1.1 INTRODUCTION & LITERATURE REVIEW 
 
 Pulmonary Aspergillosis is caused by Aspergillus fumigatus lung infection. There 
are four manifestations of Aspergillus lung infection which is include Pulmonary 
Aspergilloma, Allergic Bronchopulmonary Aspergillosis, Chronic Necrotizing or Semi 
Invasive Aspergillosis and Invasive Aspergillosis[1]. The manifestations of Aspergillus 
lung infection depends on an individual immune response.   
 
Aspergilloma is a colonization of a pre-existing lung cavity with little invasion 
of adjacent lung in normal individual immune status. Usually most of the cavities are due 
to Tuberculosis or Sarcodoisis [2]. Whereas Allergic Bronchopulmonary Aspergillosis 
(ABPA) is due to hypersensitivity reaction within the airways secondary to Aspergillus 
infection leading to wall damage, bronchiectasis and fibrosis. It is common in patient 
with poorly controlled asthma and cystic fibrosis[3]. Typically, there is elevation of 
serum IgE and positive skin test. The other spectrum is Chronic Necrotizing or Semi 
Invasive Aspergillosis. It demonstrate a more chronic disease course that seen along with 
Invasive Aspergillosis and can occur in patient with normal or mildly impaired immune 
system. Usually the treatment require long term antifungal and surgical might be 
considered [4]. 
 
 The most important spectrum in Aspergillus infection is Invasive Pulmonary 
Aspergillosis (IPA) where it affects severely immunocompromised hosts. It first 
described by Rankin and was published in1953. In early course of disease, it will affect 
the airway (Airway Invasive Aspergillosis) before further vascular invasion (Angio 
Invasive Aspergillosis) causing necrosis of the lung parenchyma. Nowadays, Invasive 
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Pulmonary Aspergillosis still remain an important cause of morbidity and mortality 
among neutropenic patient with haematological malignancies if not detected and treated 
early. Clinical symptoms of IPA includes fever, cough, haemoptysis, pleuritic chest pain 
and dyspnoea. However this clinical symptoms are nonspecific for IPA [5]. 
 
 IPA diagnosis was categorized in to Possible, Probable and Proven according to 
European Organization for Research and Treatment of Cancer/Mycosis Study Group 
(EORTC-MSG). For diagnosis of Proven Invasive Aspergillosis, it required 
histopathological confirmation which is often not permissible due to most of the 
hematological malignancy patient are at risk of bleeding complication for invasive 
procedure. It also required positive culture which is provide result in a longer time 
causing delay in diagnosis and actual antifungal treatment to be start [6]. For diagnosis 
of Probable Invasive Aspergillosis, it required positive clinical criteria and positive 
mycological test such as positive Galactomannan (GM) assay. No test for 
histopathological is needed. As consequences, they are recent studies focuses on 
noninvasive diagnostic tool including Galactomannan and Aspergillus – specific 
polymerase chain reaction (PCR) as mycological marker with medical imaging which is 
CT thorax findings to support the diagnosis [7-9]. For Possible Invasive Aspergillosis, 
the diagnosis is made based on clinical history without any positive results in either 
mycological test or histopathological test positivity. 
 
 Galactomannan is a linear hetero-polysaccharide polymer, which make up the 
specific wall of Fungi phylum. In daily practice, positive blood test for Galactomannan 
has become one of the mycological criteria accepted in EORTC-MSG. Several studied 
done regarding Galactomannan showed that GM levels may be lower in patient with 
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Airway Invasive compared to Angio Invasive and CT thorax as a complementary test for 
diagnosis of IPA [7, 10]. 
 
 Aspergillus specific -PCR is a molecular study which is not included in EORTC-
MSG criteria yet for diagnosis of Probable IPA because it is not adequately standardized 
even though it has currently become more accessible. In addition, there is always risk of 
sample contamination at the patient's bed side or laboratory by airborne spores which is 
responsible for false positive results. However, the molecular technique seem to arise 
rapid approach that could be used for diagnosis of IPA. There are two types of the 
molecular techniques include real time PCR and nested PCR. The development of real-
time PCR platforms has enhanced the quality of diagnostic PCR assays. However the 
preparation is still complex and expensive. Nested PCR is more convenience in 
preparation but notorious for contamination, but still both of this method was shown to 
be high degree of correlation to each other[9]. 
 
 Early CT thorax may provide early sign for Invasive Pulmonary Aspergillosis. It 
includes Airway Invasive and Angio Invasive type of changes. In Airway Invasive the 
changes includes tree in bud appearance and consolidation where the organism already 
infiltrates in to alveoli. As diseases progressed, further lung parenchymal changes are 
demonstrated including nodule without halo, later once vascular invasion occurred the 
nodule will have halo sign due to surrounding lung infarction. According to Greene et 
al, the halo sign is visible in 60.9% of Invasive Pulmonary Aspergillosis(IPA) cases, 
especially in the first week after the onset of infection[11]. In a retrospective study of 
IPA done by Caillot et al., reported that the halo sign was present in 92% of patients[12]. 
As soon as PMN count is >500/mm3, the nodules excavate giving an air crescent 
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sign. This image is usually observed in the immune restoration phase, around the third 
week of illness evolution. However, no CT thorax image is either sensitive or specific of 
IPA. For example the halo sign may be observed in other pathological illness such as 
metastases, bronchoalveolar carcinoma,lymphoma or systemic disease such as  Wegener 
granulomatosis[13]. 
 
 The Proven IPA only can be diagnosed once patient had histopathological 
findings which is not permissible to be done in patient with hematological malignancy.  
Positive Aspergillus culture is time consuming causing delayed in diagnosing IPA. Even 
though the gold standard for IPA diagnosis is Proven IPA, Probable IPA also can be 
considered as definite diagnosis. With that, the mycological test need to be conjunction 
with imaging findings for early diagnosis to be made. In advance, the empirical 
antifungal treatment can be start without any doubt and delay. 
 
 The purpose of this study is to determine association of blood serological test for 
Galactomannan assay and Aspergillus specific -PCR with CT thorax findings and further 
to analyses the predominant CT findings either Airway Invasive or Angio Invasive. Other 
than that, this study will provide the type of CT thorax findings or changes for patient 
with Possible and Probable Pulmonary Aspergillosis which be helpful for clinician to 
diagnosed and start the empirical antifungal treatment in patient who fulfilled clinical 
criteria for IPA especially in hospital without facilities to provide the mycological test. 
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CHAPTER 2: STUDY PROTOCOL 
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2.1 TITLE 
Association of CT thorax findings with Galactomannan and Aspergillus - specific 
Polymerase Chain Reaction for diagnosis of Invasive Aspergillosis in patient with febrile 
neutropenia. 
2.2 OBJECTIVE 
2.2.1 General objective 
To determine association of CT thorax findings in patient with Invasive Pulmonary 
Aspergillosis with Galactomannan and Aspergillus-specific Polymerase Chain Reaction. 
 
2.2.2 Specific objectives 
1.  To determine association between CT thorax findings with Galactomannan result 
in patient with febrile neutropenia. 
2.  To determine association between CT thorax findings with Aspergillus-specific 
Polymerase Chain Reaction result in patient with febrile neutropenia. 
 
2.3 METHODOLOGY 
2.3.1 Study design 
This is a cross sectional study conducted at Hospital Universiti Sains Malaysia (HUSM), 
Kubang Kerian Kelantan from January 2015 until November 2017.  
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2.3.2 Population and Sample 
Reference population: Patient with hematological malignancy. 
Source population: Patient with hematological malignancy and febrile   
neutropenia who received chemotherapy or hematopoietic stem cell transplant. 
Study participant: Patient with haematological malignancy who received 
chemotherapy or haematopoietic stem cell transplant and complicated with 
persistent febrile neutropenia despite on antibiotic for 3 days or more with CT 
thorax. 
2.3.3 Sampling method  
Purposive sampling method. 
2.3.4 Inclusion Criteria 
1. Patient with haematological malignancy admitted to haematological ward 
(Age >12 year old). 
2. Neutropenia following chemotherapy with absolute neutrophil count (ANC) 
<0.5 x 109/L. 
 3. Persistent fever 3 days or more despite on appropriate broad-spectrum      
 antibiotic given. 
 4. Patient with CT Thorax within 2 weeks of clinical diagnosis of Possible IPA. 
 
2.3.5 Exclusion Criteria 
 1. Patients who are positive human immunodeficiency virus (HIV). 
 2. Patients with positive bacteraemia. 
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3. Patients with previously diagnosed Proven and Probable invasive fungal   
infections according to (EORTC/MSG) which is not completed antifungal 
treatment (8weeks). 
4. Patient with concomitant malignancies other than haematological 
malignancies. 
2.3.6 Sample Size Calculation 
For both objective 1 and 2: 
Sample size is calculated using Sample Size Calculator version 1.7, updated August 2015 
from website: www.medic.usm.my/biostat, using 2 proportions-Hypothesis testing. 
Proportion in control (p0) = estimated proportion of study outcome in the unexposed 
group (airway invasive CT finding). 
Proportion in case (p1) = estimated proportion of study outcome in the exposed group 
(Angio Invasive CT finding). 
p0 =43%   p1 = 7%               (M.Weisser, 2005),  
Significance level (alpha) 0.05. 
Power of study (1- β) of 80% 
Total sample size obtained including 10% of drop out is 24 patient. 
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Total patient to be sampled taken from sample size calculation is 24. 
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2.3.7 Research Tools 
1. CT scan machine -Siemens SOMATOM Definition AS+ which is capable of 
producing 128-slices of images per rotation. 
2.  Picture Archive Communication System (PACS) in HUSM. (PACS Universal Viewer 
Version 5.0 SP6). 
3.  Diagnostic workstation with 2 Mega Pixel monitor- (Barco MPG 2121 monitor– 
resolution 2048 x 1536). 
 
2.3.8 Operational definition 
1. Fever:  Temperature > 38⁰C recorded more than 1 Hour or >38.5⁰C recorded once. 
2. Neutropenia: Absolute neutrophil count (ANC) < 0.5 x 109/L or< 1.0 x 109/L if rapid 
decrease was predicted in the following 24-48 hours. 
3. Persistent febrile neutropenia: Persistent fever 3 days or more despite of broad-
spectrum antibiotic. 
4. Possible, Probable and Proven Invasive Aspergillosis:  Defined according to the 
European Organization for Research and Treatment of Cancer-Mycoses Study Group 
(Figure 1). 
-Proven invasive fungal disease (IFD) requires positive mycological criteria. 
-Probable IFD requires the presence of a host factor, a clinical criterion, and a   
mycological criterion.  
-Possible IFD requires a host factor and a clinical criterion but for which 
mycological criteria are absent. 
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5. CT thorax findings:  
Divided in to 2 category: 
 1: Airway Invasive: 
 - Tree in bud : Peripheral branching structure with ground glass opacity. 
- Consolidation: Opacities with obscuration of the underlying vessels. 
 
 2: Angio Invasive. 
- Nodule with halo : Nodule with surrounding ground glass opacities (area          
of hazy increased attenuation without obscuration of 
underlying vascular marking). 
 - Nodule without halo : Nodule with no surrounding ground glass opacities. 
 - Air crescent sign : Crescent-shaped or circumferential area of radiolucency 
                 within a parenchymal consolidation or nodular opacity. 
- Cavity  : Lucent area surrounded by wall within lung parenchyma. 
(Reference: L. Beth Gadkowski, 2008 and Greene et al, 2007) 
 
2.3.9 Patients recruitment and mycological test. 
- Patient who presented to medical team with haematological malignancy and 
febrile neutropenia and suspected for Invasive Pulmonary Aspergillosis will be 
recruited by primary team. 
- Blood test for Galactomannan and Aspergillus specific -PCR will be perform 
by medical team. 
- Patient are then referred to radiology department by medical team for CT thorax 
(part of routine investigation) and early appointment date within two weeks will 
be given . 
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 - Blood sample result for Galactomannan and Aspergillus specific -PCR will be 
 trace from microbiology team. 
 - An optical density (OD) of 0.5 and higher in any serum of Galactomannan 
 sample will be considered positive result (Based on EORTC-MSG criteria). 
  - Galactomannan result classified into 2 category: 
  1. Negative: less than 0.5 OD     
2. Positive: 0.5 and more OD 
2.3.10 Image analysis: 
- All subjects underwent CT Thorax using MDCT scanner (SOMATOM Sensation 
cardiac 128; Siemens AG, Munich, Germany) 
-Scan were performed craniocaudally using 69 mAs, 100 - 120 kVp and reconstructed 
with: 
 1) B70f (lung setting), Window Width 1200 and Centre -600. 
 2) B26f (soft tissue setting), Window Width 400 and Centre 40. 
- Intravenous iodinated low osmolar contrast media 300 to 320mgI/ml, 70ml and flush 
with 50ml of normal saline using injector at rate of 3 mls / second. 
-Images were reviewed by Radiologist more than 10 years of experienced.  
-Blood for Galactomannan and Aspergillus-specific PCR result was blinded to avoid 
bias. 
2.3.11 Statistical analysis  
Analysis of both objectives (objective 1 and 2) in this study were performed using PASW 
version 18. We used a Fisher Exact test for categorical variables.  
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2.3.12 Confidentiality and Privacy  
We give serial number for each of the patient. No identifiable data were expressed and 
shared to the public resulting from this study.  
 
2.3.13 Ethical Consideration  
This study was approved by Jawatankuasa Etika Penyelidikan (Manusia) of Universiti 
Sains Malaysia (JEPeM) which is the Research and Ethical Committee of Universiti 
Sains Malaysia (JEPeM code: USM/JEPeM/16010006) which complies with the 
Declaration of Helsinki (Appendix B). 
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MAIN DOCUMENT 
3.2 TITLE 
 ASSOCIATION OF CT THORAX FINDINGS WITH GALACTOMANNAN 
AND ASPERGILLUS - SPECIFIC POLYMERASE CHAIN REACTION FOR 
DIAGNOSIS OF INVASIVE ASPERGILLOSIS IN PATIENT WITH FEBRILE 
NEUTROPENIA. 
3.3 ABSTRACT 
Background: The Computed tomography (CT) features of Invasive Pulmonary 
Aspergillosis (IPA) include Airway and Angio Invasive type. However those features are 
nonspecific and diagnosis should be made in conjunction with EORTC-MSG criteria. In 
this study, we evaluated the association between the CT findings and Galactomannan 
and Aspergillus specific PCR in patient with febrile neutropenia. 
 
Methods: Patients with hematological malignancy who had persistent febrile 
neutropenia of 3 days or more despite of antibiotic underwent CT thorax within 2 weeks 
of clinical diagnosis of IPA. Blood serum for Galactomannan assay and Aspergillus -
specific PCR were performed. Changes of CT thorax were documented and association 
between mycological findings were analyzed using Fisher exact test.  Significant 
association taken at p value of < 0.05.  
 
Results: A total of 26 patients were enrolled in our study. CT findings were positive in 
17(65.4%), 8(30.8%) was positive for Galactomannan and 9(34.6%) for PCR. There was 
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significant association between PCR and CT thorax finding (p value 0.009, 95% CI) but 
not between Galactomannan and CT Thorax (p value 0.667, 95% CI). 
 
Conclusion: Combination of PCR and CT thorax promised reliable non-invasive tools 
for early diagnosis of IPA. The Aspergillus specific PCR might to be consider as one of 
the mycological criteria in EORTC-MSG for diagnosis of IPA in the future. 
 
Keywords: Invasive Pulmonary Aspergillosis, galactomannan, Polymerase chain 
reaction, Radiography thoracic, febrile neutropenia 
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3.4 INTRODUCTION 
 Pulmonary Aspergillosis is caused by Aspergillus fumigatus lung infection. There 
are four manifestations of Aspergillus lung infection which is include Pulmonary 
Aspergilloma, Allergic Bronchopulmonary Aspergillosis, Chronic Necrotizing or Semi 
Invasive Aspergillosis and Invasive Aspergillosis[1]. The manifestations of Aspergillus 
lung infection depends on an individual immune response.   
 
The most important spectrum in Aspergillus infection is Invasive Pulmonary 
Aspergillosis (IPA) where it affects severely immunocompromised hosts. It first 
described by Rankin and was published in1953. In early course of disease, it will affect 
the airway (Airway Invasive Aspergillosis) before further vascular invasion (Angio 
Invasive Aspergillosis) causing necrosis of the lung parenchyma. 
 
The diagnosis of Invasive Pulmonary Aspergillosis (IPA), continues as a 
challenging diagnosis to some groups of patient especially whom with underlying 
haematological malignancies. The worst is, most of the hematological malignancies 
patients with febrile neutropenia are at greatest risk for fungal infection. The common 
organism is Aspergillus and  its incidence was estimated around 10-15%[2]. The delayed 
in diagnosis and initiation of empirical antifungal treatment will lead to increasing in 
severity of IPA and in turns associated with high morbidity and mortality [3]. 
 
 Based on European Organization for Research and Treatment of Cancer/Mycosis 
Study Group (EORTC-MSG) diagnosis of IPA was categorized into three which is 
Proven IPA, Probable IPA and Possible IPA. Histopathological or cultured based of 
Aspergillus is the gold standard for diagnosis of Proven IPA, whereas the diagnosis of 
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Probable IPA is made when Galactomannan (GM) is positive. The diagnosis of Possible 
IPA only required clinical evidence of IPA as included in EORTC-MSG criteria. 
 
 Galactomannan is a linear hetero-polysaccharide polymer, which make up the 
specific wall of Fungi phylum. In daily practice, positive blood test for Galactomannan 
has become one of the mycological criteria accepted in EORTC-MSG. This is because 
GM has high specificity (85 – 99%) even though the sensitivity is broad (29 – 94%) [2, 
4].  
 
 Aspergillus specific -PCR is a molecular study which is not included in EORTC-
MSG criteria yet for diagnosis of Probable IPA because it is not adequately standardized 
even though it has currently become more accessible. In addition, there is always risk of 
sample contamination at the patient's bed side or laboratory by airborne spores which is 
responsible for false positive results. However, the molecular technique seem to arise 
rapid approach that could be used for diagnosis of IPA. There are two types of the 
molecular techniques include real time PCR and nested PCR. The development of real-
time PCR platforms has enhanced the quality of diagnostic PCR assays. However the 
preparation is still complex and expensive. Nested PCR is more convenience in 
preparation but notorious for contamination, but still both of this method was shown to 
be high degree of correlation to each other[5]. 
  
There were few recent studies that compare the GM and PCR performance in 
patient with IPA, showed that PCR had high sensitivity and specificity up to 100% and 
88% respectively[6, 7]. However both of that study was not correlate with CT Thorax 
findings. 
